380 related articles for article (PubMed ID: 29150490)
21. Chemoembolization and bland embolization: a critical appraisal.
Befeler AS
Clin Liver Dis; 2005 May; 9(2):287-300, vii. PubMed ID: 15831274
[TBL] [Abstract][Full Text] [Related]
22. Advances in Local and Systemic Therapies for Hepatocellular Cancer.
Mokdad AA; Singal AG; Yopp AC
Curr Oncol Rep; 2016 Feb; 18(2):9. PubMed ID: 26769114
[TBL] [Abstract][Full Text] [Related]
23. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.
Brown ZJ; Hewitt DB; Pawlik TM
Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184
[TBL] [Abstract][Full Text] [Related]
24. Nonsurgical treatment of hepatocellular carcinoma.
Llovet JM; Sala M; Bruix J
Liver Transpl; 2000 Nov; 6(6 Suppl 2):S11-5. PubMed ID: 11084079
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular carcinoma: latest developments.
Walzer N; Kulik LM
Curr Opin Gastroenterol; 2008 May; 24(3):312-9. PubMed ID: 18408459
[TBL] [Abstract][Full Text] [Related]
26. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
[TBL] [Abstract][Full Text] [Related]
27. Liver-directed therapy for hepatocellular carcinoma.
Narsinh KH; Duncan DP; Newton IG; Minocha J; Rose SC
Abdom Radiol (NY); 2018 Jan; 43(1):203-217. PubMed ID: 29230556
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the treatment of hepatocellular carcinoma.
Padhya KT; Marrero JA; Singal AG
Curr Opin Gastroenterol; 2013 May; 29(3):285-92. PubMed ID: 23507917
[TBL] [Abstract][Full Text] [Related]
29. Management of hepatocellular carcinoma.
Asham EH; Kaseb A; Ghobrial RM
Surg Clin North Am; 2013 Dec; 93(6):1423-50. PubMed ID: 24206860
[TBL] [Abstract][Full Text] [Related]
30. How we approach it: treatment options for hepatocellular carcinoma.
Hernaez R; El-Serag HB
Am J Gastroenterol; 2018 Jun; 113(6):791-794. PubMed ID: 29713029
[No Abstract] [Full Text] [Related]
31. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Kikuchi L; Oliveira CP; Alvares-da-Silva MR; Tani CM; Diniz MA; Stefano JT; Chagas AL; Alencar RS; Vezozzo DC; Santos GR; Campos PB; Alves VA; Ratziu V; Carrilho FJ
Am J Clin Oncol; 2016 Oct; 39(5):428-32. PubMed ID: 25268068
[TBL] [Abstract][Full Text] [Related]
33. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study.
Shin J; Yu JH; Jin YJ; Suh YJ; Kim DH; Byun S; Lee JW
Medicine (Baltimore); 2019 Jul; 98(30):e16150. PubMed ID: 31348228
[TBL] [Abstract][Full Text] [Related]
34. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
Sun JY; Yin T; Zhang XY; Lu XJ
J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Jeng WJ; Lin CC; Chen WT; Sheen IS; Lin CY; Lin SM
Dig Dis; 2014; 32(6):747-54. PubMed ID: 25376293
[TBL] [Abstract][Full Text] [Related]
38. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.
Al-Shamsi HO; Abdel-Wahab R; Hassan MM; Shalaby AS; Dahbour I; Lacin S; Mahvash A; Odisio BC; Murthy R; Avritscher R; Abdelsalam ME; Rashid A; Vauthey JN; Aloia TA; Conrad C; Chun YS; Krishnan S; Das P; Koay EJ; Amin HM; Yao JC; Kaseb AO
Oncology; 2017; 93(4):233-242. PubMed ID: 28683459
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
[TBL] [Abstract][Full Text] [Related]
40. [Hepatocellular carcinoma].
Czauderna C; Marquardt JU; Galle PR; Wörns MA
Internist (Berl); 2017 May; 58(5):469-479. PubMed ID: 28386626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
